PharmiWeb

Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...
PharmiWeb

Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple ...
PR Newswire

Multiple System Atrophy Market Set to Experience Significant Growth with Breakthrough Therapies by 2034 | DelveInsight

The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...
PR Newswire

Multiple System Atrophy Market to Register Immense Growth at a CAGR of 4% by 2032 | DelveInsight

With the expected launch of emerging therapies, the multiple system atrophy market is expected to show positive growth in the forecast period in the 7MM. Moreover, increased awareness of MSA has ...
Mena FN

Multiple System Atrophy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Theravance Biopharma, Alterity Therapeutics, Askbio, Kainos ...

"Multiple System Atrophy Pipeline"DelveInsight's,“Multiple System Atrophy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Multiple System ...
Mena FN

Multiple System Atrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approvals By Delveinsight Neuramedy, Promis Neurosciences, Enterin Inc ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing ...
Yahoo Finance

Drug that reduces iron levels in affected brain regions has a possible disease-modifying effect in people with multiple system atrophy

HONOLULU, Oct. 5, 2025 /PRNewswire/ -- An orally administered drug to redistribute excess iron and lower cellular oxidative stress was found to slow disease progression of multiple system atrophy (MSA ...
Monthly Prescribing Reference

Emrusolmin Fast Tracked for Multiple System Atrophy

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
The Manila Times

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity” or 'the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Yahoo Finance

Multiple System Atrophy (MSA) Market is expected to reach US$ 202.3 Million by 2031, Report by CoherentMI

The growth of the MSA market is attributed to the increasing research and developmental activities to develop disease modifying therapies for MSA. For instance, in 2020, Neuraly raised $15 million in ...
Huffington Post UK

Multiple System Atrophy: A Continued Battle With MSA

Whilst families can feel helpless in the battle against MSA (or any degenerative illness with no cure) Alfie and his family are proof to us all that the rays of hope and positivity can shine down ...